Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | PREP | P48147 | 4/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1885718 | 1.00 | CHRM2 (0.47) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL71243 | 1.00 | CHRM2 (0.47) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL16908277 | 1.00 | CHRM2 (0.47) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL15508352 | 1.00 | CHRM2 (0.47) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL15508459 | 1.00 | CHRM2 (0.47) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL31137064 | 0.87 | CHRM2 (0.41) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL1006280 | 0.85 | CHRM2 (0.40) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL1005463 | 0.85 | CHRM2 (0.40) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL1005464 | 0.85 | CHRM2 (0.40) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL17717511 | 0.85 | CHRM2 (0.40) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2900665-A1 | TRIAZOLYL DERIVATIVES AS SYK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-08-05 | — | — | EP | disclosed |
| EP-1961750-B1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO CO LTD (JP) | 2013-09-18 | — | — | EP | disclosed |
| US-20130065882-A1 | VLA-4 inhibitory drug | MACHINAGA NOBUO (JP) | 2013-03-14 | — | — | US | disclosed |
| US-20120157437-A1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-06-21 | — | — | US | disclosed |
| US-8129366-B2 | VLA-4 inhibitory drug | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-06 | — | — | US | disclosed |
| US-7947833-B2 | methods that are useful in the preparation of amidophenyl-sulfonylamino-quinoxaline compounds CCK2 modulators are disclosed by sulfonylation | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-24 | — | — | US | disclosed |
| US-20090233901-A1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-17 | — | — | US | disclosed |
| US-7563895-B2 | Quinoxaline compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-07-21 | — | — | US | disclosed |
| EP-1961750-A1 | VLA-4 INHIBITORY DRUG | Daiichi Sankyo Company, Limited (JP) | 2008-08-27 | — | — | EP | disclosed |
| EP-1651621-B1 | 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS AS CCK2 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-08-06 | — | — | EP | disclosed |
| US-7304051-B2 | Quinoxaline compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-04 | — | — | US | disclosed |
| US-7288651-B2 | Preparation of quinoxaline compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-30 | — | — | US | disclosed |
| EP-1651622-B1 | PROCESS FOR THE PREPARATION OF 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2007-02-07 | — | — | EP | disclosed |
| CN-1863782-A | 2-(quinoxalin-5-ylsulfonylamino)-benzamide compounds as cck2 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2006-11-15 | — | — | CN | disclosed |
| EP-1651622-A1 | PROCESS FOR THE PREPARATION OF 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS | Janssen Pharmaceutica N.V. (BE) | 2006-05-03 | — | — | EP | disclosed |
| EP-1651621-A1 | 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS AS CCK2 MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005016896-A1 | 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS AS CCK2 MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-24 | — | — | WO | disclosed |
| WO-2005016897-A1 | PROCESS FOR THE PREPARATION OF 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-24 | — | — | WO | disclosed |
| US-20050043310-A1 | Preparation of quinoxaline compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-24 | — | — | US | disclosed |
| US-20050038032-A1 | Quinoxaline compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157437-A1 | VLA-4 INHIBITORY DRUG | VCAM1, ITGB4, ITGA4 | CHRM2 1896/4885CHRM1 1078/4885CHRM3 1886/4885 |
| US-20130065882-A1 | VLA-4 inhibitory drug | VCAM1, ITGB4, ITGA4 | CHRM2 2230/4885CHRM1 1293/4885CHRM3 2168/4885 |
| US-20050043310-A1 | Preparation of quinoxaline compounds | CCKAR, CCKBR, GIPR | CHRM2 1192/4885CHRM1 1440/4885CHRM3 977/4885 |
| US-20050038032-A1 | Quinoxaline compounds | CCKAR, CCKBR, GIPR | CHRM2 2459/4885CHRM1 3225/4885CHRM3 2630/4885 |
| US-20090233901-A1 | VLA-4 INHIBITORY DRUG | VCAM1, ITGB4, ITGA4 | CHRM2 2033/4885CHRM1 1300/4885CHRM3 2253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.